drugset / Trial / NCT06602219
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Phase 2
Completed
222 enrolled
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.
Timeline
- Start
- 2024-10-25
- Primary completion
- 2025-07-24
- Completion
- 2025-09-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY4100511 | Unknown | — | Oral |